Global Tuberculosis Treatment Market Report and Forecast 2023-2031

Global Tuberculosis Treatment Market Report and Forecast 2023-2031

Global Tuberculosis Treatment Market Outlook

The global tuberculosis (TB) treatment market size was valued at USD 1.8 billion in 2022 and is projected to grow at a CAGR of 6.7% during the forecast period of 2023-2031 to reach a value of USD 3.2 billion by 2031. The market growth can be attributed to the increasing prevalence of tuberculosis, the rising awareness about TB, and advancements in TB diagnostics and treatment options.

Global Tuberculosis Treatment Market: Introduction

Tuberculosis treatment refers to the medical care provided to individuals with tuberculosis, a highly infectious bacterial disease primarily affecting the lungs. The increasing prevalence of tuberculosis is driving the demand for TB treatment. Other factors such as rising awareness about TB, increasing government initiatives, and the growing demand for innovative treatment options are also expected to drive market growth.

Advancements in technology have played a significant role in the growth of the tuberculosis treatment market. The development of rapid and accurate diagnostic tools has made it easier to identify and treat individuals with TB. In addition, the introduction of new drugs and treatment regimens has improved the effectiveness of TB treatment and reduced the duration of therapy. The tuberculosis treatment market is expected to continue to grow in the coming years, as awareness of TB increases, and new treatment options and technologies are developed to meet the needs of people with TB. However, there are still significant barriers to accessing TB treatment, particularly in low- and middle-income countries, where access to TB services is often limited. Efforts are underway to address these barriers and improve access to tuberculosis treatment globally.

Tuberculosis Epidemiology

According to the World Health Organization, tuberculosis remains one of the top 10 causes of death worldwide, with an estimated 10 million people falling ill with TB in 2020. Approximately 1.4 million people died from TB in the same year. TB can affect people of all ages, but certain populations are more vulnerable, such as those living in low- and middle-income countries, people with weakened immune systems, and individuals living in close contact with TB patients.

It is important to recognize that TB treatment should be tailored to meet the individual needs of each person, and efforts to improve access to TB treatment should consider the unique needs of different populations, as well as the underlying factors that contribute to the spread of TB, such as poverty, malnutrition, and overcrowding. By addressing these factors, we can work towards reducing the burden of tuberculosis and improving access to effective treatment for all individuals.

Tuberculosis Treatment Market Segmentations

The market can be segmented based on drug class, therapy type, disease type, distribution channel, and region:

Market Breakup by Diseases Type

  • Active Tuberculosis
  • Latent Tuberculosis
Market Breakup by Therapy Type
  • First Line Therapy
  • Second Line Therapy
Market Breakup by Route of Administration
  • Oral
  • Parenteral
  • Others
Market Breakup by Dosage Form
  • Tablets
  • Capsules
  • Injections
  • Others
Market Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Market Breakup by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others
Tuberculosis Treatment Market Scenario

The global tuberculosis treatment market has experienced significant growth over the past few years, driven by factors such as the increasing prevalence of tuberculosis, rising awareness about TB, and the growing demand for innovative treatment options. One key driver of growth in the tuberculosis treatment market is the increasing prevalence of TB, particularly in low- and middle-income countries.

North America is currently the largest market for tuberculosis treatment, accounting for a significant share of the global market. The region's large market share is driven by factors such as a well-established healthcare infrastructure, strong investment in TB research and development, and effective public health programs for TB control. Europe is also a significant market for tuberculosis treatment, with countries such as the UK, Germany, and France leading the way. The region's market growth is driven by factors such as a well-established healthcare system and government initiatives to address TB concerns. Asia Pacific is another region that is experiencing significant growth in the tuberculosis treatment market. The region's market growth is driven by factors such as a large population base, increasing awareness of TB, and the growing adoption of innovative TB diagnostics and treatments. In addition, government initiatives to address TB concerns are helping to drive the growth of the market in the region.

Key Players in the Global Tuberculosis Treatment Market

The report provides a detailed analysis of the key players involved in the tuberculosis treatment market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:
  • Johnson And Johnson Services, Inc.
  • Lupin Ltd
  • Novartis AG
  • Macleods Pharmaceuticals Ltd.
  • Otsuka Pharmaceutical Co., Ltd
  • Pfizer Inc.
  • AstraZeneca Plc
  • Cipla Ltd
  • Alkem Laboratories Ltd
  • Eli Lilly And Company
  • F. Hoffmann-La Roche Ltd.
  • Viatris Inc. (Mylan N.V.)
  • Teva Pharmaceutical Industries, Ltd.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Tuberculosis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Tuberculosis Treatment Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Tuberculosis Epidemiology (2016-2031)
5.3 Europe Tuberculosis Epidemiology (2016-2031)
5.4 Asia-Pacific Tuberculosis Epidemiology (2016-2031)
5.5 Latin America Tuberculosis Epidemiology (2016-2031)
5.6 Middle East & Africa Tuberculosis Epidemiology (2016-2031)
6 Global Tuberculosis Treatment Market Overview
6.1 Global Tuberculosis Treatment Market Historical Value (2016-2022)
6.2 Global Tuberculosis Treatment Market Forecast Value (2023-2031)
7 Global Tuberculosis Treatment Market Landscape
7.1 Tuberculosis Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Tuberculosis Treatment: Product Landscape
7.2.1 Analysis by Product
7.2.2 Analysis by End User
8 Tuberculosis Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Tuberculosis Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Tuberculosis Treatment Market Segmentation
11.1 Global Tuberculosis Treatment Market by Disease Type
11.1.1 Market Overview
11.1.2 Active Tuberculosis
11.1.3 Latent Tuberculosis
11.2 Global Tuberculosis Treatment Market by Therapy Type
11.2.1 Market Overview
11.2.2 First Line Therapy
11.2.3 Second Line Therapy
11.3 Global Tuberculosis Treatment Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parenteral
11.3.4 Others
11.4 Global Tuberculosis Treatment Market by Dosage Form
11.4.1 Market Overview
11.4.2 Tablets
11.4.3 Capsules
11.4.4 Injections
11.4.5 Others
11.5 Global Tuberculosis Treatment Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacy
11.5.3 Retail Pharmacy
11.5.4 Online Pharmacy
11.6 Global Tuberculosis Treatment Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.3 Europe
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Tuberculosis Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Tuberculosis Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Tuberculosis Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Tuberculosis Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Tuberculosis Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Johnson and Johnson Services, Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Lupin Ltd
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Novartis AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Macleods Pharmaceuticals Ltd.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Otsuka Pharmaceutical Co., Ltd
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Pfizer Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 AstraZeneca Plc
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Cipla Ltd
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Alkem Laboratories Ltd
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Eli Lilly And Company
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 F. Hoffmann-La Roche Ltd.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Viatris Inc. (Mylan N.V.)
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Teva Pharmaceutical Industries, Ltd.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
24 Tuberculosis Treatment - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings